Ola Myklebost

  • Project leader; Professor, dr. philos
  • +47-5548 4565

Ola Myklebost is Senior Scientist and part-time Project Leader at the Department of Tumor Biology, Institute for Cancer Research, and Professor at the Department of Clinical Science at the University of Bergen. His new web page is at myklebost.uib.no.

 

Publications 2024

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O, Clancy T (2023)
The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
Front Immunol, 14, 1226445
DOI 10.3389/fimmu.2023.1226445, PubMed 37799721

Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M et al. (2023)
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Science, 379 (6629), 253-260
DOI 10.1126/science.abj4784, PubMed 36656928

Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023)
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential
Mol Oncol, 17 (11), 2432-2450
DOI 10.1002/1878-0261.13514, PubMed 37622176

Publications 2022

Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022)
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Leukemia, 36 (7), 1887-1897
DOI 10.1038/s41375-022-01597-y, PubMed 35643867

Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind GE, Meza-Zepeda LA (2022)
miR-486-5p expression is regulated by DNA methylation in osteosarcoma
BMC Genomics, 23 (1), 142
DOI 10.1186/s12864-022-08346-6, PubMed 35172717

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Genome Med, 14 (1), 86
DOI 10.1186/s13073-022-01090-2, PubMed 35948919

Publications 2021

Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021)
Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour
Pathology, 53 (6), 713-719
DOI 10.1016/j.pathol.2020.11.010, PubMed 33745702

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
PLoS One, 16 (3), e0248140
DOI 10.1371/journal.pone.0248140, PubMed 33690666

Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2021)
Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer
Int J Cancer, 149 (11), 1955-1960
DOI 10.1002/ijc.33749, PubMed 34310709

Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barreca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Bérard P, Burchill SA, Brennan B, Strauss SJ et al. (2021)
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Nat Commun, 12 (1), 3230
DOI 10.1038/s41467-021-23445-w, PubMed 34050156

Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021)
Methylation-dependent SUMOylation of the architectural transcription factor HMGA2
Biochem Biophys Res Commun, 552, 91-97
DOI 10.1016/j.bbrc.2021.02.099, PubMed 33744765

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
The expressed mutational landscape of microsatellite stable colorectal cancers
Genome Med, 13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Publications 2020

Dörnen J, Myklebost O, Dittmar T (2020)
Cell Fusion of Mesenchymal Stem/Stromal Cells and Breast Cancer Cells Leads to the Formation of Hybrid Cells Exhibiting Diverse and Individual (Stem Cell) Characteristics
Int J Mol Sci, 21 (24)
DOI 10.3390/ijms21249636, PubMed 33348862

Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020)
Accurate 3-gene-signature for early diagnosis of liposarcoma progression
Clin Sarcoma Res, 10, 4
DOI 10.1186/s13569-020-0126-1, PubMed 32158531

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Cells, 8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Publications 2018

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
Patterns of genomic evolution in advanced melanoma
Nat Commun, 9 (1), 2665
DOI 10.1038/s41467-018-05063-1, PubMed 29991680

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
Int J Mol Sci, 19 (4)
DOI 10.3390/ijms19040969, PubMed 29570692

Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
PLoS One, 13 (5), e0197456
DOI 10.1371/journal.pone.0197456, PubMed 29771965

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Nakken S, Fournous G, Vodák D, Aasheim LB, Myklebost O, Hovig E (2018)
Personal Cancer Genome Reporter: variant interpretation report for precision oncology
Bioinformatics, 34 (10), 1778-1780
DOI 10.1093/bioinformatics/btx817, PubMed 29272339

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Mol Cancer Ther, 17 (11), 2473-2480
DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488

Serguienko A, Wang MY, Myklebost O (2018)
Real-Time Vital Mineralization Detection and Quantification during In Vitro Osteoblast Differentiation
Biol Proced Online, 20, 14
DOI 10.1186/s12575-018-0079-4, PubMed 30078998

Strauss SJ, Anninga J, Baglio R, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton-Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018)
Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
Clin. Sarcoma Res., 8, 17
DOI 10.1186/s13569-018-0103-0

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
Sample-Index Misassignment Impacts Tumour Exome Sequencing
Sci Rep, 8 (1), 5307
DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Publications 2017

Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O et al. (2017)
Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
Nat Commun, 8, 15936
DOI 10.1038/ncomms15936, PubMed 28643781

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
Sci Rep, 7 (1), 9655
DOI 10.1038/s41598-017-10189-1, PubMed 28848235

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
Int J Cancer, 141 (1), 184-190
DOI 10.1002/ijc.30726, PubMed 28387924

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
BMC Cancer, 17 (1), 29
DOI 10.1186/s12885-016-2992-8, PubMed 28061772

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Haematologica, 102 (7), 1266-1272
DOI 10.3324/haematol.2016.160564, PubMed 28385781

Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E (2017)
PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance
Stem Cells Dev, 26 (19), 1375-1383
DOI 10.1089/scd.2017.0129, PubMed 28805158

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Genome Med, 9 (1), 46
DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA et al. (2016)
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Lancet Oncol, 17 (9), 1261-71
DOI 10.1016/S1470-2045(16)30147-4, PubMed 27498913

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
PLoS One, 11 (9), e0163859
DOI 10.1371/journal.pone.0163859, PubMed 27685995

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Front Genet, 7, 85
DOI 10.3389/fgene.2016.00085, PubMed 27242894

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
Oncotarget, 7 (34), 54583-54595
DOI 10.18632/oncotarget.10518, PubMed 27409346

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ et al. (2016)
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 26 (5), 717.2
DOI 10.1101/gr.206557.116, PubMed 27197245

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D et al. (2016)
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report
Clin Sarcoma Res, 6, 3
DOI 10.1186/s13569-016-0043-5, PubMed 27315524

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA (2016)
Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
Oncotarget, 7 (5), 5273-88
DOI 10.18632/oncotarget.6567, PubMed 26672768

Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P (2016)
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
Oncotarget, 7 (1), 433-45
DOI 10.18632/oncotarget.6336, PubMed 26595521

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res, 76 (17), 5092-102
DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532

Publications 2015

Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O (2015)
Genome sequencing in research requires a new approach to consent
Tidsskr Nor Laegeforen, 135 (22), 2031-2
DOI 10.4045/tidsskr.15.0944, PubMed 26627287

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ et al. (2015)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
Genome Res, 25 (6), 814-24
DOI 10.1101/gr.190470.115, PubMed 25963125

Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
Genomic landscape of liposarcoma
Oncotarget, 6 (40), 42429-44
DOI 10.18632/oncotarget.6464, PubMed 26643872

Myklebost O (2015)
Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls
Per Med, 12 (6), 593-602
DOI 10.2217/pme.15.20, PubMed 29750616

Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK (2015)
Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death
Mol Cancer, 14 (1), 14
DOI 10.1186/s12943-014-0278-9, PubMed 25623255

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
Blood Cancer J, 5 (3), e299
DOI 10.1038/bcj.2015.24, PubMed 25794135

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
Oncotarget, 6 (4), 2451-65
DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jurgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss S, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M et al. (2014)
Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology
Clin. Sarcoma Res., 4, 4
DOI 10.1186/2045-3329-4-4

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014)
Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model
Mol Cancer, 13, 93
DOI 10.1186/1476-4598-13-93, PubMed 24885297

Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014)
Performance comparison of four exome capture systems for deep sequencing
BMC Genomics, 15 (1), 449
DOI 10.1186/1471-2164-15-449, PubMed 24912484

Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014)
The architecture and evolution of cancer neochromosomes
Cancer Cell, 26 (5), 653-67
DOI 10.1016/j.ccell.2014.09.010, PubMed 25517748

Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA (2014)
The regulatory landscape of osteogenic differentiation
Stem Cells, 32 (10), 2780-93
DOI 10.1002/stem.1759, PubMed 24898411

Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014)
Generation and characterization of an immortalized human mesenchymal stromal cell line
Stem Cells Dev, 23 (19), 2377-89
DOI 10.1089/scd.2013.0599, PubMed 24857590

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP et al. (2014)
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Science, 345 (6196), 1251343
DOI 10.1126/science.1251343, PubMed 25082706

Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
PLoS One, 9 (8), e103873
DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF et al. (2013)
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Nat Genet, 45 (12), 1479-82
DOI 10.1038/ng.2814, PubMed 24162739

Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F (2013)
Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas
Genes Chromosomes Cancer, 52 (6), 580-90
DOI 10.1002/gcc.22055, PubMed 23508853

Doorn J, Fernandes HA, Le BQ, van de Peppel J, van Leeuwen JP, De Vries MR, Aref Z, Quax PH, Myklebost O, Saris DB, van Blitterswijk CA, de Boer J (2013)
A small molecule approach to engineering vascularized tissue
Biomaterials, 34 (12), 3053-63
DOI 10.1016/j.biomaterials.2012.12.037, PubMed 23369216

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM (2013)
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
BMC Cancer, 13, 245
DOI 10.1186/1471-2407-13-245, PubMed 23688189

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O (2013)
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
Br J Cancer, 109 (8), 2228-36
DOI 10.1038/bjc.2013.549, PubMed 24064976

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013)
Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
Transl Oncol, 6 (5), 546-53
DOI 10.1593/tlo.13457, PubMed 24151535

Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013)
Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome
Exp Cell Res, 319 (14), 2230-43
DOI 10.1016/j.yexcr.2013.06.004, PubMed 23791939

Skårn M, Barøy T, Stratford EW, Myklebost O (2013)
Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells
PLoS One, 8 (11), e79231
DOI 10.1371/journal.pone.0079231, PubMed 24236112

Stratford EW, Bostad M, Castro R, Skarpen E, Berg K, Høgset A, Myklebost O, Selbo PK (2013)
Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity
Biochim Biophys Acta, 1830 (8), 4235-43
DOI 10.1016/j.bbagen.2013.04.033, PubMed 23643966

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O (2013)
The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines
Cancer Med, 3 (1), 36-46
DOI 10.1002/cam4.170, PubMed 24403055

Publications 2012

Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012)
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
PLoS One, 7 (11), e48262
DOI 10.1371/journal.pone.0048262, PubMed 23144859

Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM (2012)
Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
Genes Chromosomes Cancer, 51 (7), 696-706
DOI 10.1002/gcc.21956, PubMed 22454324

Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O (2012)
Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
Sarcoma, 2012, 639038
DOI 10.1155/2012/639038, PubMed 22518090

Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012)
Modulation of the osteosarcoma expression phenotype by microRNAs
PLoS One, 7 (10), e48086
DOI 10.1371/journal.pone.0048086, PubMed 23133552

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O (2012)
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Cancer, 119 (5), 1013-22
DOI 10.1002/cncr.27837, PubMed 23165797

Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O (2012)
[Genome sequencing for personalized cancer treatment]
Tidsskr Nor Laegeforen, 132 (21), 2406-8
DOI 10.4045/tidsskr.12.0784, PubMed 23160594

Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak S, Munthe E, Myklebost O (2012)
Characterization of liposarcoma cell lines for preclinical and biological studies
Sarcoma, 2012, 148614
DOI 10.1155/2012/148614, PubMed 22911243

Publications 2011

Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM (2011)
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
Clin Cancer Res, 17 (8), 2110-9
DOI 10.1158/1078-0432.CCR-10-2047, PubMed 21372215

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011)
Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
Cancer, 118 (2), 558-70
DOI 10.1002/cncr.26276, PubMed 21713766

Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011)
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
BMC Med Genomics, 4, 66
DOI 10.1186/1755-8794-4-66, PubMed 21933437

Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O (2011)
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
BMC Cancer, 11, 211:1-11
DOI 10.1186/1471-2407-11-211, PubMed 21624110

Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (2011)
Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222
Stem Cells Dev, 21 (6), 873-83
DOI 10.1089/scd.2010.0503, PubMed 21756067

Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O (2011)
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
Clin Sarcoma Res, 1 (1), 8
DOI 10.1186/2045-3329-1-8, PubMed 22612877

Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MH, Picci P, Whelan JS, Hogendoorn PC, Bielack SS (2011)
Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology
J Adolesc Young Adult Oncol, 1 (3), 118-23
DOI 10.1089/jayao.2012.0005, PubMed 26811922

Publications 2010

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Blood, 116 (9), 1489-97
DOI 10.1182/blood-2010-03-272278, PubMed 20505157

Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SA, Kassem M, Myklebost O (2010)
Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells
BMC Cancer, 10, 329
DOI 10.1186/1471-2407-10-329, PubMed 20576167

Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2010)
DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation
PLoS One, 5 (11), e15378
DOI 10.1371/journal.pone.0015378, PubMed 21085701

Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA (2010)
Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours
BMC Res Notes, 3, 223
DOI 10.1186/1756-0500-3-223, PubMed 20691109

Mayordomo E, Machado I, Giner F, Kresse SH, Myklebost O, Carda C, Navarro S, Llombart-Bosch A (2010)
A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models
Appl Immunohistochem Mol Morphol, 18 (5), 453-61
DOI 10.1097/PAI.0b013e3181daace3, PubMed 20436344

Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010)
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort
Genes Chromosomes Cancer, 49 (1), 40-51
DOI 10.1002/gcc.20717, PubMed 19787792

Tenstad E, Tourovskaia A, Folch A, Myklebost O, Rian E (2010)
Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device
Lab Chip, 10 (11), 1401-1409
DOI 10.1039/b926738g, PubMed 20386793

Publications 2009

Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA (2009)
LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
Genes Chromosomes Cancer, 48 (8), 679-93
DOI 10.1002/gcc.20675, PubMed 19441093

Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E, Myklebost O (2009)
Upregulation of stem cell genes in multidrug resistant K562 leukemia cells
Leuk Res, 33 (10), 1379-85
DOI 10.1016/j.leukres.2009.03.028, PubMed 19394083

Myklebost O (2009)
Stamcellenes mørke side
In P2-akademiet, Transit, [Oslo], [Nr] XLI, s. 165-175
BIBSYS 093863438

Myklebost O, Noordhuis P (2009)
Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: Role of TGF beta/BMP-6 and TIEG1 in chemotherapy escape. (vol 123, pg 2759, 2008)
Int. J. Cancer, 124 (9), 2250
DOI 10.1002/ijc.24300

Publications 2008

Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2008)
DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH
Mol Cancer, 7, 48
DOI 10.1186/1476-4598-7-48, PubMed 18522746

Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990

Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008)
High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence
J Cell Mol Med, 12 (2), 553-63
DOI 10.1111/j.1582-4934.2007.00146.x, PubMed 18419597

Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO (2008)
Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization
Oncol Rep, 20 (4), 825-43
DOI 10.3892/or_00000080, PubMed 18813824

Publications 2007

Francis P, Namløs HM, Müller C, Edén P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M (2007)
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential
BMC Genomics, 8, 73
DOI 10.1186/1471-2164-8-73, PubMed 17359542

Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
Mol Cancer, 6, 2
DOI 10.1186/1476-4598-6-2, PubMed 17201907

Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O (2007)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Int J Cancer, 121 (1), 199-205
DOI 10.1002/ijc.22643, PubMed 17354236

Publications 2006

Berner JM, Muller CR, Holden M, Wang J, Hovig E, Myklebost O (2006)
Sampling effects on gene expression data from a human tumour xenograft
Scand. J. Lab. Anim. Sci., 33 (1), 17-30

MAQC Consortium, Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK et al. (2006)
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
Nat Biotechnol, 24 (9), 1151-61
DOI 10.1038/nbt1239, PubMed 16964229

Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006)
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
Cancer Res, 66 (18), 8984-93
DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739

Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
Leukemia, 20 (3), 539-42
DOI 10.1038/sj.leu.2404094, PubMed 16437153

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Proc Natl Acad Sci U S A, 103 (6), 1888-93
DOI 10.1073/pnas.0507493103, PubMed 16443686

Publications 2005

Agesen TH, Flørenes VA, Molenaar WM, Lind GE, Berner JM, Plaat BE, Komdeur R, Myklebost O, van den Berg E, Lothe RA (2005)
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 64 (1), 74-81
DOI 10.1093/jnen/64.1.74, PubMed 15715087

Bjerkehagen B, Myklebost O (2005)
[Molecular genetics in the diagnosis of bone and soft tissue tumours]
Tidsskr Nor Laegeforen, 125 (23), 3286-9
PubMed 16327856

Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM, Stokke T (2005)
Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
Leukemia, 19 (12), 2313-23
DOI 10.1038/sj.leu.2403954, PubMed 16193090

Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, Gray JW, Forus A, Myklebost O (2005)
Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH
Mol Cancer, 4, 39
DOI 10.1186/1476-4598-4-39, PubMed 16274472

Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
Int J Cancer, 115 (6), 935-42
DOI 10.1002/ijc.20962, PubMed 15723354

Nygaard V, Holden M, Løland A, Langaas M, Myklebost O, Hovig E (2005)
Limitations of mRNA amplification from small-size cell samples
BMC Genomics, 6, 147
DOI 10.1186/1471-2164-6-147, PubMed 16253144

Publications 2004

Cekaite L, Haug O, Myklebost O, Aldrin M, Østenstad B, Holden M, Frigessi A, Hovig E, Sioud M (2004)
Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method
Proteomics, 4 (9), 2572-82
DOI 10.1002/pmic.200300768, PubMed 15352232

Lyng H, Badiee A, Svendsrud DH, Hovig E, Myklebost O, Stokke T (2004)
Profound influence of microarray scanner characteristics on gene expression ratios: analysis and procedure for correction
BMC Genomics, 5 (1), 10
DOI 10.1186/1471-2164-5-10, PubMed 15018648

Myklebost O (2004)
Putting Norway on the gene-therapy map
Nature, 429 (6988), 129
DOI 10.1038/429129b, PubMed 15141186

Nilbert M, Meza-Zepeda LA, Francis P, Berner JM, Namløs HM, Fernebro J, Myklebost O (2004)
Lessons from genetic profiling in soft tissue sarcomas
Acta Orthop Scand Suppl, 75 (311), 35-50
DOI 10.1080/00016470410001708310, PubMed 15188664

Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N (2004)
Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas
Int J Cancer, 109 (3), 363-9
DOI 10.1002/ijc.11716, PubMed 14961574

Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J (2004)
Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma
J Mol Diagn, 6 (4), 297-307
DOI 10.1016/S1525-1578(10)60525-9, PubMed 15507668

Wang J, Meza-Zepeda LA, Kresse SH, Myklebost O (2004)
M-CGH: analysing microarray-based CGH experiments
BMC Bioinformatics, 5, 74
DOI 10.1186/1471-2105-5-74, PubMed 15189572

Publications 2003

Andersen K, Smith-Sørensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad Ø, Maelandsmo GM (2003)
Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
Br J Cancer, 88 (12), 1995-2001
DOI 10.1038/sj.bjc.6600998, PubMed 12799648

Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A (2003)
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation
Oncogene, 22 (34), 5358-61
DOI 10.1038/sj.onc.1206671, PubMed 12917637

Maire G, Forus A, Foa C, Bjerkehagen B, Mainguené C, Kresse SH, Myklebost O, Pedeutour F (2003)
11q13 alterations in two cases of hibernoma: large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5
Genes Chromosomes Cancer, 37 (4), 389-95
DOI 10.1002/gcc.10223, PubMed 12800150

Nygaard V, Løland A, Holden M, Langaas M, Rue H, Liu F, Myklebost O, Fodstad Ø, Hovig E, Smith-Sørensen B (2003)
Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance
BMC Genomics, 4 (1), 11
DOI 10.1186/1471-2164-4-11, PubMed 12659661

Wang J, Bø TH, Jonassen I, Myklebost O, Hovig E (2003)
Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data
BMC Bioinformatics, 4, 60
DOI 10.1186/1471-2105-4-60, PubMed 14651757

Wang J, Myklebost O, Hovig E (2003)
MGraph: graphical models for microarray data analysis
Bioinformatics, 19 (17), 2210-1
DOI 10.1093/bioinformatics/btg298, PubMed 14630649

Publications 2002

Jenssen TK, Langaas M, Kuo WP, Smith-Sørensen B, Myklebost O, Hovig E (2002)
Analysis of repeatability in spotted cDNA microarrays
Nucleic Acids Res, 30 (14), 3235-44
DOI 10.1093/nar/gkf441, PubMed 12136105

Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
Oncogene, 21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409

Wang J, Delabie J, Aasheim H, Smeland E, Myklebost O (2002)
Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study
BMC Bioinformatics, 3, 36
DOI 10.1186/1471-2105-3-36, PubMed 12445336

Wang J, Nygaard V, Smith-Sørensen B, Hovig E, Myklebost O (2002)
MArray: analysing single, replicated or reversed microarray experiments
Bioinformatics, 18 (8), 1139-40
DOI 10.1093/bioinformatics/18.8.1139, PubMed 12176840

Xie Y, Skytting B, Nilsson G, Grimer RJ, Mangham CD, Fisher C, Shipley J, Bjerkehagen B, Myklebost O, Larsson O (2002)
The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery
Oncogene, 21 (37), 5791-6
DOI 10.1038/sj.onc.1205700, PubMed 12173050

Publications 2001

Forus A, Bjerkehagen B, Sirvent N, Meza-Zepeda LA, Coindre JM, Berner JM, Myklebost O, Pedeutour F (2001)
A well-differentiated liposarcoma with a new type of chromosome 12-derived markers
Cancer Genet Cytogenet, 131 (1), 13-8
DOI 10.1016/s0165-4608(01)00516-7, PubMed 11734312

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
Oncogene, 20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967

Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O (2001)
Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases
Cancer Genet Cytogenet, 125 (2), 100-11
DOI 10.1016/s0165-4608(00)00369-1, PubMed 11369052

Forus A, Sørlie T, Børresen-Dale AL, Myklebost O (2001)
[Microarray technology--potential in cancer research]
Tidsskr Nor Laegeforen, 121 (21), 2498-503
PubMed 11875927

Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
[Gene therapy in cancer]
Tidsskr Nor Laegeforen, 121 (4), 482-8
PubMed 11255868

Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O (2001)
Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions
Genes Chromosomes Cancer, 31 (3), 264-73
DOI 10.1002/gcc.1143, PubMed 11391797

Sandvik AK, Støren O, Nørsett K, Laegreid A, Børresen-Dale AL, Myklebost O (2001)
[Measurement of gene activity by DNA microarrays]
Tidsskr Nor Laegeforen, 121 (10), 1225-8
PubMed 11402749

Publications 2000

Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R (2000)
Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma
Cancer Genet Cytogenet, 118 (2), 89-98
DOI 10.1016/s0165-4608(99)00178-8, PubMed 10748288

Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM, Pedeutour F (2000)
Characterization of centromere alterations in liposarcomas
Genes Chromosomes Cancer, 29 (2), 117-29
DOI 10.1002/1098-2264(2000)9999:9999<::aid-gcc1014>3.0.co;2-q, PubMed 10959091

Publications 1999

Berner JM, Sørlie T, Mertens F, Henriksen J, Saeter G, Mandahl N, Brøgger A, Myklebost O, Lothe RA (1999)
Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway
Genes Chromosomes Cancer, 26 (2), 151-60
DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A, PubMed 10469453

Forus A, Høifødt HK, Overli GE, Myklebost O, Fodstad O (1999)
Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates
Mol Pathol, 52 (2), 68-74
DOI 10.1136/mp.52.2.68, PubMed 10474684

Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C (1999)
Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors
Genes Chromosomes Cancer, 24 (1), 30-41
DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.3.CO;2-G, PubMed 9892106

Simons A, Schepens M, Forus A, Godager L, van Asseldonk M, Myklebost O, van Kessel AG (1999)
A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis
Genes Chromosomes Cancer, 26 (2), 115-24
DOI 10.1002/(SICI)1098-2264(199910)26:2<115::AID-GCC3>3.0.CO;2-E, PubMed 10469449

Wolf M, Tarkkanen M, Hulsebos T, Larramendy ML, Forus A, Myklebost O, Aaltonen LA, Elomaa I, Knuutila S (1999)
Characterization of the 17p amplicon in human sarcomas: microsatellite marker analysis
Int J Cancer, 82 (3), 329-33
DOI 10.1002/(sici)1097-0215(19990730)82:3<329::aid-ijc4>3.0.co;2-1, PubMed 10399948

Publications 1998

Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O (1998)
Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas
Br J Cancer, 78 (4), 495-503
DOI 10.1038/bjc.1998.521, PubMed 9716033

Myklebost O (1998)
[Molecular biology diagnosis of sarcoma]
Tidsskr Nor Laegeforen, 118 (14), 2188-93
PubMed 9656816

Myklebost O (1998)
GLI gene and rhabdomyosarcoma
Nat Med, 4 (8), 869
DOI 10.1038/nm0898-869c, PubMed 9701218

Publications 1997

Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Böhling T, Asko-Seljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA, Tukiainen E, Caballín MR, Myklebost O, Knuutila S (1997)
Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization
Br J Cancer, 75 (10), 1403-9
DOI 10.1038/bjc.1997.242, PubMed 9166930

Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O (1997)
HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas
Oncogene, 14 (24), 2935-41
DOI 10.1038/sj.onc.1201135, PubMed 9205100

Geurts van Kessel A, dos Santos NR, Simons A, de Bruijn D, Forus A, Fodstad O, Myklebost O, Balemans M, Baats E, Olde Weghuis D, Suijkerbuijk RF, van den Berg E, Molenaar WM, de Leeuw B (1997)
Molecular cytogenetics of bone and soft tissue tumors
Cancer Genet Cytogenet, 95 (1), 67-73
DOI 10.1016/s0165-4608(96)00241-5, PubMed 9140455

Wolf M, Aaltonen LA, Szymanska J, Tarkkanen M, Blomqvist C, Berner JM, Myklebost O, Knuutila S (1997)
Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis
Genes Chromosomes Cancer, 18 (1), 66-70
DOI 10.1002/(sici)1098-2264(199701)18:1<66::aid-gcc8>3.0.co;2-#, PubMed 8993982

Publications 1996

Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O (1996)
Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas
Genes Chromosomes Cancer, 17 (4), 254-9
DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2, PubMed 8946207

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

Myklebost O (1996)
First for biotech
Nature, 384 (6606), 208
DOI 10.1038/384208b0, PubMed 8918866

Publications 1995

Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A (1995)
Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas
Genes Chromosomes Cancer, 14 (1), 15-21
DOI 10.1002/gcc.2870140104, PubMed 8527379

Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, van Kessel AG (1995)
Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas
Genes Chromosomes Cancer, 14 (1), 8-14
DOI 10.1002/gcc.2870140103, PubMed 8527390

Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
DNA Cell Biol, 14 (3), 251-6
DOI 10.1089/dna.1995.14.251, PubMed 7880445

Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
Br J Cancer, 72 (2), 393-8
DOI 10.1038/bjc.1995.344, PubMed 7640224

Van Roy N, Forus A, Myklebost O, Cheng NC, Versteeg R, Speleman F (1995)
Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP
Cancer Genet Cytogenet, 82 (2), 151-4
DOI 10.1016/0165-4608(95)00034-m, PubMed 7664245

Publications 1994

Flørenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O (1994)
Expression of the neuroectodermal intermediate filament nestin in human melanomas
Cancer Res, 54 (2), 354-6
PubMed 8275467

Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994)
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
J Natl Cancer Inst, 86 (17), 1297-302
DOI 10.1093/jnci/86.17.1297, PubMed 8064888

Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O (1994)
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
Cancer Genet Cytogenet, 78 (2), 165-71
DOI 10.1016/0165-4608(94)90085-x, PubMed 7828148

Forus A, Kools PF, Schoenmakers EF, Van de Ven WJ, Myklebost O (1994)
A long range restriction map spanning the myxoid liposarcoma breakpoint in the q13-14 region of human chromosome 12
Hum Genet, 94 (3), 259-64
DOI 10.1007/BF00208280, PubMed 8076941

Suijkerbuijk RF, Olde Weghuis DE, Van den Berg M, Pedeutour F, Forus A, Myklebost O, Glier C, Turc-Carel C, Geurts van Kessel A (1994)
Comparative genomic hybridization as a tool to define two distinct chromosome 12-derived amplification units in well-differentiated liposarcomas
Genes Chromosomes Cancer, 9 (4), 292-5
DOI 10.1002/gcc.2870090410, PubMed 7519052

Publications 1993

ANDREASSEN A, BORRESEN AL, OYJORD T, SOLHEIM OP, FLORENES VA, BRULAND O, MYKLEBOST O, HOIE J, FODSTAD O (1993)
CHROMOSOME-17P ABERRATIONS AND P53 EXPRESSION IN HUMAN SARCOMAS
FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 419-422

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179

Brzozowska A, Fries R, Womack JE, Grimholt U, Myklebost O, Rogne S (1993)
Isolation, sequencing, and expression analysis of a bovine apolipoprotein E (APOE) cDNA and chromosomal localization of the APOE locus
Mamm Genome, 4 (1), 53-7
DOI 10.1007/BF00364665, PubMed 8422503

Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993)
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
Cell Growth Differ, 4 (12), 1065-70
PubMed 8117620

Publications 1992

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624

Forus A, Myklebost O (1992)
A physical map of a 1.3-Mb region on the long arm of chromosome 12, spanning the GLI and LRP loci
Genomics, 14 (1), 117-20
DOI 10.1016/s0888-7543(05)80292-7, PubMed 1427818

Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR (1992)
Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo
Eur J Clin Invest, 22 (4), 229-34
DOI 10.1111/j.1365-2362.1992.tb01456.x, PubMed 1499639

Publications 1991

Rogne S, Myklebost O, Olving JH, Kyrkjebø HT, Jonassen R, Olaisen B, Gedde-Dahl T (1991)
The human genes for complement components 6 (C6) and 9 (C9) are closely linked on chromosome 5
J Med Genet, 28 (9), 587-90
DOI 10.1136/jmg.28.9.587, PubMed 1683409

Publications 1990

Myklebost O, Rogne S, Hjermann I, Olaisen B, Prydz H (1990)
Association analysis of lipid levels and apolipoprotein restriction fragment length polymorphisms
Hum Genet, 86 (2), 209-14
DOI 10.1007/BF00197707, PubMed 1979958

Rogne S, Mevåg B, Gedde-Dahl T, Myklebost O (1990)
Multiple RFLPs of human complement component nine (C9) detected by TaqI
Nucleic Acids Res, 18 (10), 3112
DOI 10.1093/nar/18.10.3112-a, PubMed 1971940

Rogne S, Myklebost O (1990)
The molecular genetics of genes in lipid metabolism
University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 900815221, ISBN 82-90187-68-8

Publications 1989

Myklebost O, Arheden K, Rogne S, Geurts van Kessel A, Mandahl N, Herz J, Stanley K, Heim S, Mitelman F (1989)
The gene for the human putative apoE receptor is on chromosome 12 in the segment q13-14
Genomics, 5 (1), 65-9
DOI 10.1016/0888-7543(89)90087-6, PubMed 2548950

Nenseter MS, Myklebost O, Blomhoff R, Drevon CA, Nilsson A, Norum KR, Berg T (1989)
Low-density-lipoprotein receptors in different rabbit liver cells
Biochem J, 261 (2), 587-93
DOI 10.1042/bj2610587, PubMed 2549976

Rogne S, Myklebost O, Høyheim B, Olaisen B, Gedde-Dahl T (1989)
The genes for apolipoprotein all (APOA2) and the Duffy blood group (FY) are linked on chromosome 1 in man
Genomics, 4 (2), 169-73
DOI 10.1016/0888-7543(89)90296-6, PubMed 2500391

Rogne S, Myklebost O, Stanley K, Geurts van Kessel A (1989)
The gene for human complement C9 is on chromosome 5
Genomics, 5 (1), 149-52
DOI 10.1016/0888-7543(89)90100-6, PubMed 2767685

Publications 1988

Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK (1988)
Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor
EMBO J, 7 (13), 4119-27
DOI 10.1002/j.1460-2075.1988.tb03306.x, PubMed 3266596

Myklebost O, Rogne S (1988)
A physical map of the apolipoprotein gene cluster on human chromosome 19
Hum Genet, 78 (3), 244-7
DOI 10.1007/BF00291670, PubMed 2894348

Publications 1987

Rogne S, Skretting G, Larsen F, Myklebost O, Mevåg B, Carlson LA, Holmquist L, Gjone E, Prydz H (1987)
The isolation and characterisation of a cDNA clone for human lecithin:cholesterol acyl transferase and its use to analyse the genes in patients with LCAT deficiency and fish eye disease
Biochem Biophys Res Commun, 148 (1), 161-9
DOI 10.1016/0006-291x(87)91090-4, PubMed 2823801

Publications 1986

Myklebost O, Rogne S (1986)
The gene for human apolipoprotein CI is located 4.3 kilobases away from the apolipoprotein E gene on chromosome 19
Hum Genet, 73 (4), 286-9
DOI 10.1007/BF00279087, PubMed 3017837

Rogne S, Myklebost O, Olaisen B, Gedde-Dahl T, Prydz H (1986)
Confirmation of the close linkage between the loci for human apolipoproteins AI and AIV by the use of a cloned cDNA probe and two restriction site polymorphisms
Hum Genet, 72 (1), 68-71
DOI 10.1007/BF00278820, PubMed 3002953

Publications 1985

Rogne S, Rønning OW, Myklebost O, Seglen PO, Pettersen EO (1985)
Cell cycle traverse and protein metabolism in human NHIK 3025 cells: the role of anchorage
J Cell Physiol, 125 (3), 528-32
DOI 10.1002/jcp.1041250324, PubMed 4066771

Shaw DJ, Meredith AL, Sarfarazi M, Huson SM, Brook JD, Myklebost O, Harper PS (1985)
The apolipoprotein CII gene: subchromosomal localisation and linkage to the myotonic dystrophy locus
Hum Genet, 70 (3), 271-3
DOI 10.1007/BF00273455, PubMed 2991117

Publications 1984

Humphries SE, Williams L, Myklebost O, Stalenhoef AF, Demacker PN, Baggio G, Crepaldi G, Galton DJ, Williamson R (1984)
Familial apolipoprotein CII deficiency: a preliminary analysis of the gene defect in two independent families
Hum Genet, 67 (2), 151-5
DOI 10.1007/BF00272990, PubMed 6547689

Myklebost O, Rogne S, Olaisen B, Gedde-Dahl T, Prydz H (1984)
The locus for apolipoprotein CII is closely linked to the apolipoprotein E locus on chromosome 19 in man
Hum Genet, 67 (3), 309-12
DOI 10.1007/BF00291359, PubMed 6088388

Myklebost O, Williamson B, Markham AF, Myklebost SR, Rogers J, Woods DE, Humphries SE (1984)
The isolation and characterization of cDNA clones for human apolipoprotein CII
J Biol Chem, 259 (7), 4401-4
PubMed 6546757

Publications 1983

Humphries SE, Jowett NI, Williams L, Rees A, Vella M, Kessling A, Myklebost O, Lydon A, Seed M, Galton DJ (1983)
A DNA polymorphism adjacent to the human apolipoprotein CII gene
Mol Biol Med, 1 (5), 463-71
PubMed 6094958

Publications 1981

Myklebost O (1981)
Hepatocyte fusion: A critical discussion of the mechanism of artificial cellfusion and an experimental study of the possibilities and limitations of cell fusion techniques applied to isolated rat hepatocytes, including polyethyleneglycol-mediated fusion, sendai virus-mediated fusion and erythrocyte ghost-mediated microinjection
O. Myklebust, Oslo, 175 s.
BIBSYS 961353198

Page visits: 39082